WHWK (Whitehawk Therapeutics) Research & Development: $99.41 Mil (TTM As of Mar. 2026)


WHWK Whitehawk Therapeutics Inc WHWK
38 GF Score
Price $4.11
GF Value $0.27
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Whitehawk Therapeutics Research & Development?

Whitehawk Therapeutics WHWK -6.16% 38 Research & Development is $99.41 Mil as of Mar. 2026. GuruFocus rates WHWK with a GF Score™ of 38/100 and a GF Value™ of $0.27 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Whitehawk Therapeutics's Research & Development for the three months ended in Mar. 2026 was $17.23 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $99.41 Mil.

Whitehawk Therapeutics  (NAS:WHWK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Whitehawk Therapeutics Research & Development Related Terms

Whitehawk Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Whitehawk Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Whitehawk Therapeutics Research & Development Chart

Whitehawk Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 19.67 32.66 48.93 51.03 90.96

Whitehawk Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.79 48.81 14.35 19.02 17.23
WHWK
38GF Score
Whitehawk Therapeutics Inc WHWK
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Whitehawk Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $99.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $99.41 Mil mean?
Whitehawk Therapeutics (WHWK) has a Research & Development of $99.41 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Whitehawk Therapeutics and its competitors.
Is Whitehawk Therapeutics' Research & Development too high?
Whitehawk Therapeutics' current Research & Development is $99.41 Mil. Overall, Whitehawk Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Whitehawk Therapeutics' Research & Development compare to VYGR and CRBU?
Whitehawk Therapeutics' Research & Development of $99.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Whitehawk Therapeutics and its competitors. Whitehawk Therapeutics's current Research & Development is $99.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Whitehawk Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Whitehawk Therapeutics (WHWK) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $4.11 — trading 1422.2% above its estimated fair value. The current Research & Development is $99.41 Mil. Whitehawk Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Whitehawk Therapeutics (WHWK), the current Research & Development is $99.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Whitehawk Therapeutics (WHWK) Overvalued in 2026?

Based on GuruFocus' analysis, Whitehawk Therapeutics stock appears to be overvalued. The current stock price of $4.11 is trading 1422.2% above its estimated GF Value™ of $0.27. GuruFocus considers Whitehawk Therapeutics to be Significantly Overvalued.

Key valuation signals for WHWK:

  • Research & Development: $99.41 Mil
  • GF Value™: $0.27 vs. price of $4.11 (1422.2% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the WHWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Whitehawk Therapeutics Business Description

Other Exchanges 3350:Germany
Address 2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
38GF Score

Get the complete analysis for WHWK

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$0.27
GF Value